How To Use CPT Code 0050U

CPT 0050U describes a targeted genomic sequence analysis panel for acute myelogenous leukemia (AML). This article will cover the official description, procedure, qualifying circumstances, appropriate usage, documentation requirements, billing guidelines, historical information, and examples of CPT code 0050U.

1. What is CPT Code 0050U?

CPT 0050U is a proprietary laboratory analysis (PLA) code that applies to a specific lab test called the MyAML™ NGS Panel by LabPMM LLC. This test is a next-generation targeted sequencing (NGS) assay that analyzes 194 genes associated with acute myelogenous leukemia (AML). It interrogates the genes for sequence variants, copy number variants, and rearrangements to provide valuable information for prognosis, recurrence potential, and therapeutic options for patients with AML.

2. Official Description

The official description of CPT code 0050U is: ‘Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements.’

3. Procedure

1. The lab analyst performs targeted next-generation sequencing technology and custom software to analyze DNA from a specimen.
2. The analysis focuses on 194 genes associated with acute myelogenous leukemia (AML).
3. The sequencing technology identifies substitutions, insertions, deletions, single nucleotide variants (SNVs), indels, inversions, translocations, and copy number alterations in the genes.
4. A molecular pathologist reviews and interprets the identified mutations, classifying them as pathogenic, potentially pathogenic, and/or actionable for targeted therapy.

4. Qualifying circumstances

CPT code 0050U is used for patients with acute myelogenous leukemia (AML) who require genomic analysis of 194 genes to determine prognosis, recurrence potential, and therapeutic options. The test is performed by LabPMM LLC using their MyAML™ NGS Panel. It is important to note that this code should only be used for the specific proprietary test and not for any other similar tests.

5. When to use CPT code 0050U

CPT code 0050U should be used when ordering the MyAML™ NGS Panel by LabPMM LLC for patients with acute myelogenous leukemia (AML). It provides valuable genomic information for prognosis, recurrence potential, and therapeutic options. It is important to ensure that the test is performed by the specific lab and using the specific panel associated with CPT code 0050U.

6. Documentation requirements

To support a claim for CPT code 0050U, the following documentation is required:

• Order for the MyAML™ NGS Panel by LabPMM LLC
• Date of service
• Results of the genomic analysis, including identified mutations and their classification
• Signature of the molecular pathologist who reviewed and interpreted the results

7. Billing guidelines

When billing for CPT code 0050U, ensure that the test is performed by LabPMM LLC using their MyAML™ NGS Panel. Report one unit of this code for a single specimen analyzed on a single date of service. It is important to note that PLA codes, like CPT code 0050U, take precedence over the usual laboratory/pathology codes. Therefore, do not report this test with any other CPT codes. Some payers may also separately reimburse for specimen collection, so it is advisable to check with the appropriate payer for their specific guidelines.

8. Historical information

CPT code 0050U was added to the Current Procedural Terminology system on July 1, 2018. There have been no updates or changes to the code since its addition.

9. Examples

1. A patient with acute myelogenous leukemia (AML) undergoes the MyAML™ NGS Panel by LabPMM LLC to determine their prognosis and potential therapeutic options based on the genomic analysis.
2. A physician orders the MyAML™ NGS Panel by LabPMM LLC for a patient with AML to assess the recurrence potential after treatment and guide further management decisions.
3. A molecular pathologist reviews the results of the MyAML™ NGS Panel by LabPMM LLC for a patient with AML and identifies actionable mutations that can be targeted with specific therapies.
4. A clinician orders the MyAML™ NGS Panel by LabPMM LLC to better define therapeutic options for a patient with AML and to guide personalized treatment decisions.
5. A patient with AML undergoes the MyAML™ NGS Panel by LabPMM LLC to gain insights into their disease and potential treatment options based on the genomic alterations identified.
6. A molecular pathologist interprets the results of the MyAML™ NGS Panel by LabPMM LLC for a patient with AML, providing valuable information for prognosis and recurrence potential.
7. A physician orders the MyAML™ NGS Panel by LabPMM LLC for a patient with AML to assess the genomic alterations present and guide targeted therapy decisions.
8. A patient with AML undergoes the MyAML™ NGS Panel by LabPMM LLC to determine their eligibility for specific targeted therapies based on the identified mutations.
9. A molecular pathologist analyzes the genomic data from the MyAML™ NGS Panel by LabPMM LLC for a patient with AML, providing insights into potential therapeutic options.
10. A clinician orders the MyAML™ NGS Panel by LabPMM LLC for a patient with AML to better understand the genetic landscape of their disease and guide treatment decisions.